Read Larry Connors' blog – Short Term Trading Strategies
Stock Profiler welcomes investors to chat LIVE about these stocks and more on their upgraded website with FREE Investor Tools, Live Chats, and much more! Sign up now at www.stockprofiler.us. Companies who want to broadcast their message are encouraged to contact Stock Profiler.US, LLC at (603) 424-4420.
-------------------------------------------
Infinity Medical Group Inc. (PINKSHEETS: IMGR | Quote | Chart | News | PowerRating) closed at $0.12 Wednesday, trading 244,011 shares.
Company News- August 20, 2008: Infinity Medical Group Inc. Launches Two New Websites to Promote Its Dental Implant Clinics
Infinity Medical Group Inc. (PINKSHEETS: IMGR | Quote | Chart | News | PowerRating) is pleased to have announced earlier today that it has launched two new websites to promote its dental implant clinics. The site www.2thimplant.com is meant to promote and educate the general public about dental implants, and www.dentalimplantpartners.com is designed to promote the opportunity of joining and learning more about dental implants for dentists. Two thousand Americans will turn 50 every day (1 every 8 seconds) for the next 20 years. Studies show the number of Americans over 55 will grow by 60% in the next 20 years and their buying power will exceed $2 trillion by 2007. (Business Communications Co., Inc., February 2005).
The company is pleased with the launch of www.2thimplant.com and www.dentalimplantpartners.com. It is meant to not only increase awareness with the general public but also serves to enhance the bottom line of its clinics and provide easier access for both dentists and the patients they serve.
About Infinity Medical Group Inc.:
Infinity Medical Group Inc. is a specialty healthcare development company focusing on the building, finance and management of cosmetic medical laser and dental implant clinics offering elective procedures. For more information, please visit www.infinitymedical.com.
About Dental Implants:
Dental implants are designed as permanent replacements for missing teeth. A dental implant is a metal post that is surgically placed into the bone under the gums. The purpose of the placement into the bone is to encourage the integration of the dental implants. The bone actually grows around the dental implant, making the tooth secure. A replacement tooth is attached to the titanium post by means of a final abutment.
About Infinity Medical Group Inc.
Specializing in servicing medical, dental professionals and specialty healthcare industry in the acquisition of facilities, equipment technology, systemization, branding, containment and development.
-------------------------------------------
3SBio Inc. (Nasdaq: SSRX | Quote | Chart | News | PowerRating) closed at $9.27 Wednesday, trading 19,916 shares.
Company News- August 20, 2008: 3SBio Inc. to Hold Annual General Meeting
3SBio Inc. (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that the 2008 Annual General Meeting of Shareholders of 3SBio Inc. will be held on September 12, 2008 (Friday) at 10:00 a.m. (Beijing time) at No.3 A1, Road 10, Shenyang Economy & Technology Development Zone, Shenyang 110027, People's Republic of China.
Further information is available on the 3SBio Inc. website at http://www.3sbio.com under the heading "Investors", and additional information about 3SBio Inc. is available in its annual report on Form 20-F for the year ending December 31, 2007 filed with the U.S. Securities and Exchange Commission, which can be accessed at the following link: http://bbs.3sbio.com/en/News/ShowInfo_n16.aspx?ID=30 .
About 3SBio Inc.
3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China.
-------------------------------------------
Longs Drug Stores Corporation (NYSE: LDG | Quote | Chart | News | PowerRating) closed at $72.10 Wednesday, trading 1,207,900 shares.
Company News- August 20, 2008: Longs Drug Stores Corporation Reports Second Quarter Results
Longs Drug Stores Corporation (NYSE: LDG | Quote | Chart | News | PowerRating) yesterday reported preliminary income from continuing operations for the second quarter ended July 31, 2008 of $27.5 million, or $0.76 per diluted share, including $0.7 million of after-tax charges, or $0.02 per diluted share, related to provisions for store closures and asset impairments and legal reserves, a 6.8 percent increase compared with income from continuing operations for the second quarter ended July 26, 2007 of $25.7 million, or $0.67 per diluted share.
To read the full news release, go to www.stockprofiler.us, and click the Headline link after entering the ticker symbol.
About the Long Drugs Corpaoration
Headquartered in Walnut Creek, California, Longs Drug Stores Corporation (NYSE: LDG | Quote | Chart | News | PowerRating) is one of the most recognized retail drug store chains on the West Coast and in Hawaii. The Company operates 521 retail pharmacies and offers a wide assortment of merchandise focusing on health, wellness, beauty and convenience. Longs also provides pharmacy benefit management services and Medicare beneficiary prescription drug plans through its wholly-owned subsidiary, RxAmerica, LLC. Additional information about Longs and its services is available at http://www.longs.com and more information about RxAmerica is available at http://www.rxamerica.com.
-------------------------------------------
Chemtura Corporation (NYSE: CEM | Quote | Chart | News | PowerRating) closed at $6.36 Wednesday, trading 3,137,900 shares.
Company News- August 20, 2008: Chemtura and Venomix Extend Collaboration
Chemtura Corporation (NYSE: CEM | Quote | Chart | News | PowerRating) and Venomix, Inc. have agreed to extend their collaboration on the development of insecticides based on spider venom peptides, the companies announced yesterday. The companies began their collaboration in 2006. Since then, Chemtura has made payments to Venomix for the achievement of scientific milestones. During the extended collaboration, the companies will agree annually on research milestones and payments. The financial terms of the original agreement and the extension have not been disclosed.
The collaboration centers on the discovery that peptides contained in spider venom have insecticidal properties. Venomix has isolated and characterized a number of these peptides, which are lethal to insects but harmless to non-target species, including humans. One of these peptides, designated "hybrid," is the object of the collaboration.
The first goal of the collaboration is to develop the "hybrid" peptide as a commercial insecticide. Longer term, the companies will collaborate to produce small, chemical molecules that "fit" the same receptor as the "hybrid" peptide. This is expected to lead to chemical pesticides with the same biological activity and safety profile as the "hybrid" peptide.
John L. McIntyre, Ph.D., President and CEO of Venomix, said, "The collaboration with Chemtura has gone extremely well. We have an excellent relationship and we both see greater opportunity now from the collaboration than we did when we started."
Gregory E. McDaniel, Group President for Crop Protection, Chemtura said, "We are very excited about the hybrid peptide technology and our ongoing collaboration with Venomix. This technology has been shown to provide control against a number of commercially important crop insects and has the potential to significantly enhance our current portfolio."
About Chemtura
Chemtura Corporation, with 2007 sales of $3.7 billion, is a global manufacturer and marketer of polymer additives, performance specialties, consumer products and crop protection products. Additional information concerning Chemtura is available at http://www.chemtura.com.
Venomix is developing a new generation of insecticides using peptides from spiders. The company's technology is based on ground-breaking research conducted at the University of Connecticut. Over 50 unique, spider-venom peptides have been identified. This patented technology is exclusively licensed to Venomix. Products under development have a unique mode of action, are highly effective against insects and related pests and are harmless to non-target species, including humans. Target markets include agriculture, animal health and specialty non-crop uses such as household insects. Venomix products will be ideally suited for the environmentally conscious twenty-first century. http://www.Venomix.net -------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Stock Profiler.US, LLC's News Division, which includes but is not limited to www.stockprofiler.us, www.associatesfortune.com, www.businessnetwire.us, www.fastmoneytalk.com, www.markettelegraph.com, www.thewallstreetleader.com, financialbusinessnews.us and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.
Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes News, Media Coverage
CONTACT: StockProfiler.US Tel: +1 603 424 4420 e-mail: info@stockprofiler.us WWW: http://www.stockprofiler.us
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
